Medicare utilization — DR. RESHMA M KHAN (M.D)
Calendar year 2023 · data refreshed 2026-05-27
| HCPCS | Description | Services | Beneficiaries | Allowed | Payment |
|---|---|---|---|---|---|
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 53,200 | 25 | $0 | $208,833 |
| J0897 | Injection, denosumab, 1 mg | 2,340 | 33 | $0 | $43,153 |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 317 | 55 | $0 | $18,779 |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | 257 | 179 | $0 | $25,853 |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | 111 | 111 | $0 | $13,559 |
Service volume and Medicare payment amounts do not indicate quality of care, patient outcomes, or fraud. Data reflects Medicare fee-for-service only.
Source: CMS public data · Not endorsed by CMS · Beneficiary counts under 11 are suppressed in source data ·